Changes in hypothalamic paraventricular nucleus catecholaminergic activity after acute and chronic morphine administration.
The participation of hypothalamic noradrenaline in the expression of neuroendocrine signs of morphine withdrawal has been proposed. The present study in rats examined: (1) the relationships between corticosterone secretion and the possible modifications in noradrenaline and dopamine content and turnover in the hypothalamic paraventricular nucleus after acute and chronic morphine administration; (2) the changes in cyclic adenosine monophosphate (cAMP) levels in the paraventricular nucleus after the same treatments. The results showed that acute morphine injection in control rats increased corticosterone release, 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) production, and noradrenaline turnover. Dopamine turnover in the paraventricular nucleus was decreased and the cAMP levels remained unchanged. In chronic morphine-treated rats, there was no elevation in noradrenaline turnover or in corticosterone secretion, indicating that tolerance developed to the acute effects of the opioid. Correspondingly, no alterations in dopamine turnover were observed when chronic morphine-treated rats were compared with control rats acutely injected with morphine. cAMP levels in the paraventricular nucleus were unchanged during the tolerant state. The results raise the possibility that noradrenergic afferents play a significant role in the alterations of paraventricular nucleus function and pituitary-adrenal axis activity in response to acute and chronic morphine and suggest that these modifications are not mediated through adenylate cyclase activation. The present data provide further support for the idea of adaptive changes in noradrenergic neurons projecting to the paraventricular nucleus during chronic morphine exposure.
Fuertes
G
G
Departamento de Fisiología y Farmacología, Area de Farmacología, Facultad de Medicina, Campus de Espinardo, 30100, Murcia, Spain.
Milanés
M V
MV
Rodríguez-Gago
M
M
Marín
M T
MT
Laorden
M L
ML
D000818:Animals; D002395:Catecholamines / Q000378:metabolism*; D003345:Corticosterone / Q000097:blood; D000242:Cyclic AMP / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004361:Drug Tolerance; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D009020:Morphine / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D002395:Catecholamines; D009294:Narcotics; D008734:Methoxyhydroxyphenylglycol; D009020:Morphine; D000242:Cyclic AMP; D004298:Dopamine; D003345:Corticosterone; D009638:Norepinephrine